Free Trial

Axsome Therapeutics (AXSM) Competitors

$75.19
+1.01 (+1.36%)
(As of 04:00 PM ET)

AXSM vs. HCM, INSM, PBH, CRNX, RARE, BHVN, SMMT, PRGO, ALKS, and IDYA

Should you be buying Axsome Therapeutics stock or one of its competitors? The main competitors of Axsome Therapeutics include HUTCHMED (HCM), Insmed (INSM), Prestige Consumer Healthcare (PBH), Crinetics Pharmaceuticals (CRNX), Ultragenyx Pharmaceutical (RARE), Biohaven (BHVN), Summit Therapeutics (SMMT), Perrigo (PRGO), Alkermes (ALKS), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical preparations" industry.

Axsome Therapeutics vs.

HUTCHMED (NASDAQ:HCM) and Axsome Therapeutics (NASDAQ:AXSM) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends.

HUTCHMED has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Axsome Therapeutics has a beta of 1.13, indicating that its stock price is 13% more volatile than the S&P 500.

HUTCHMED presently has a consensus target price of $29.70, suggesting a potential upside of 59.08%. Axsome Therapeutics has a consensus target price of $121.92, suggesting a potential upside of 62.79%. Given HUTCHMED's stronger consensus rating and higher possible upside, analysts clearly believe Axsome Therapeutics is more favorable than HUTCHMED.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
HUTCHMED
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Axsome Therapeutics
0 Sell rating(s)
1 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.92

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 22.4% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

HUTCHMED has higher revenue and earnings than Axsome Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HUTCHMED$838M3.88$100.78MN/AN/A
Axsome Therapeutics$270.60M13.10-$239.24M-$6.38-11.70

Axsome Therapeutics received 110 more outperform votes than HUTCHMED when rated by MarketBeat users. Likewise, 68.67% of users gave Axsome Therapeutics an outperform vote while only 66.60% of users gave HUTCHMED an outperform vote.

CompanyUnderperformOutperform
HUTCHMEDOutperform Votes
313
66.60%
Underperform Votes
157
33.40%
Axsome TherapeuticsOutperform Votes
423
68.67%
Underperform Votes
193
31.33%

HUTCHMED has a net margin of 0.00% compared to HUTCHMED's net margin of -118.07%. Axsome Therapeutics' return on equity of 0.00% beat HUTCHMED's return on equity.

Company Net Margins Return on Equity Return on Assets
HUTCHMEDN/A N/A N/A
Axsome Therapeutics -118.07%-87.17%-32.81%

In the previous week, Axsome Therapeutics had 6 more articles in the media than HUTCHMED. MarketBeat recorded 8 mentions for Axsome Therapeutics and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.75 beat Axsome Therapeutics' score of 0.26 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
HUTCHMED
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Axsome Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Axsome Therapeutics beats HUTCHMED on 11 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AXSM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AXSM vs. The Competition

MetricAxsome TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3.54B$6.74B$5.02B$8.00B
Dividend YieldN/A2.73%2.81%3.93%
P/E Ratio-11.709.71122.1214.48
Price / Sales13.10257.592,526.2775.51
Price / CashN/A35.7135.9531.61
Price / Book24.635.905.414.58
Net Income-$239.24M$139.39M$104.34M$213.99M
7 Day Performance-2.51%-2.39%-1.63%-1.55%
1 Month Performance4.85%1.35%2.51%2.71%
1 Year Performance8.57%-6.63%3.12%7.20%

Axsome Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
HCM
HUTCHMED
2.2874 of 5 stars
$21.40
-1.7%
$29.70
+38.8%
+42.4%$3.73B$838M0.001,988Gap Down
INSM
Insmed
4.5487 of 5 stars
$25.45
-1.5%
$44.38
+74.4%
+23.2%$3.78B$305.21M-4.87373
PBH
Prestige Consumer Healthcare
4.5057 of 5 stars
$71.43
+1.3%
$110.00
+54.0%
+5.8%$3.55B$1.13B-43.55560Analyst Downgrade
CRNX
Crinetics Pharmaceuticals
4.387 of 5 stars
$49.38
+3.0%
$58.42
+18.3%
+115.7%$3.89B$1.97M-13.06290Analyst Forecast
News Coverage
RARE
Ultragenyx Pharmaceutical
4.2893 of 5 stars
$40.97
+0.0%
$87.85
+114.4%
-22.4%$3.41B$442.59M-5.101,276
BHVN
Biohaven
3.3488 of 5 stars
$37.25
+10.3%
$51.63
+38.6%
+119.0%$3.29B$462.51M-5.45239Gap Down
SMMT
Summit Therapeutics
1.7794 of 5 stars
$4.69
-2.5%
$7.50
+60.1%
+154.1%$3.29B$700,000.00-29.28105News Coverage
Positive News
Gap Down
PRGO
Perrigo
4.9876 of 5 stars
$30.26
-1.8%
$40.67
+34.4%
-15.0%$4.13B$4.66B-432.299,140Positive News
ALKS
Alkermes
4.8474 of 5 stars
$24.49
-0.9%
$35.38
+44.4%
-19.4%$4.14B$1.66B9.682,100Analyst Forecast
IDYA
IDEAYA Biosciences
2.5941 of 5 stars
$41.80
+1.8%
$46.80
+12.0%
+75.6%$3.16B$15.51M-20.80124

Related Companies and Tools

This page (NASDAQ:AXSM) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners